Holen Sie sich die Stockscreener-App
7.845
0.20%
-0.045
Schlusskurs vom Vortag:
$7.89
Offen:
$7.82
24-Stunden-Volumen:
1.48M
Relative Volume:
0.85
Marktkapitalisierung:
$920.16M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.07M
KGV:
-27.05
EPS:
-0.29
Netto-Cashflow:
$-31.85M
1W Leistung:
+15.12%
1M Leistung:
+36.47%
6M Leistung:
+101.39%
1J Leistung:
+165.13%
1-Tages-Spanne:
$7.74
$7.99
1-Wochen-Bereich:
$6.67
$8.11
52-Wochen-Spanne:
$2.36
$8.11
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Firmenname
Trevi Therapeutics Inc
Sektor
Branche
Telefon
203-304-2499
Adresse
195 CHURCH STREET, NEW HAVEN, CT
Vergleichen Sie TRVI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
7.845 | 852.28M | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.19 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.92 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.46 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
589.03 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.04 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-05-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-10 | Bestätigt | Needham | Buy |
| 2025-03-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-30 | Eingeleitet | Raymond James | Outperform |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-04-12 | Eingeleitet | B. Riley Securities | Buy |
| 2022-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-06-03 | Eingeleitet | Needham | Buy |
| 2019-06-03 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | Stifel | Buy |
Alle ansehen
Trevi Therapeutics Inc Aktie (TRVI) Neueste Nachrichten
Is Trevi Therapeutics Inc. a good long term investmentHigh-yield trading alerts - Autocar Professional
What drives Trevi Therapeutics Inc. stock priceRapid market gains - Autocar Professional
The Business Case For Buying Trevi Therapeutics Inc (NASDAQ: TRVI) Stock Now - Stocksregister
Trevi Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference - Seeking Alpha
What analysts say about Trevi Therapeutics Inc. stockPhenomenal capital gains - jammulinksnews.com
Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism - Eastern Progress
How Trevi Therapeutics Inc. stock performs during market volatilityFree Access to Investors Club - Newser
Trevi Therapeutics Inc. Stock Analysis and ForecastSuperior stock selection - Autocar Professional
Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) high institutional ownership speaks for itself as stock continues to impress, up 17% over last week - simplywall.st
Why Trevi Therapeutics Inc. stock attracts strong analyst attentionSolid Return Trade Selections - Newser
What makes Trevi Therapeutics Inc. stock price move sharplyFree Smart Investment Opportunities - Newser
Trevi Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio™ (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis - The Globe and Mail
Trevi Therapeutics (TRVI) Price Target Predicts 231.05% Upside Potential - AInvest
Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know - Yahoo Finance
31,359 Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Purchased by Vontobel Holding Ltd. - Defense World
Cantor Fitzgerald Comments on TRVI FY2025 Earnings - Defense World
Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism | TRVI Stock News - GuruFocus
Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism. - AInvest
Trevi Therapeutics, Inc.(NasdaqGM: TRVI) dropped from Russell 3000 Value Index - MarketScreener
Cough in Idiopathic Pulmonary Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Algernon Pharma, Seyltx, Melius Pharma, NeRRe Therapeutics, Trevi Therapeutics - Barchart.com
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Trevi Therapeutics Stockholders Approve Key Amendments - TipRanks
Leerink Partnrs Issues Optimistic Estimate for TRVI Earnings - Defense World
Oppenheimer Raises Price Target for Trevi Therapeutics by $3 - MSN
Squarepoint Ops LLC Acquires Shares of 14,059 Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares - Eastern Progress
WilmerHale Advises Trevi Therapeutics, Inc. in $115 Million Public Offering - WilmerHale
Two Sigma Advisers LP Invests $66,000 in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Two Sigma Investments LP Purchases New Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Rating Lowered to “Sell” at Wall Street Zen - Defense World
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Purchased by Millennium Management LLC - Defense World
Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins - insights.citeline.com
Trevi Therapeutics Closes Public Offering - MarketScreener
Finanzdaten der Trevi Therapeutics Inc-Aktie (TRVI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Trevi Therapeutics Inc-Aktie (TRVI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SCIASCIA THOMAS | Chief Scientific Officer |
Mar 25 '25 |
Sale |
6.60 |
2,631 |
17,365 |
221,373 |
| GOOD JENNIFER L | President & CEO |
Mar 21 '25 |
Option Exercise |
1.43 |
5,263 |
7,526 |
218,576 |
| GOOD JENNIFER L | President & CEO |
Mar 21 '25 |
Sale |
6.58 |
5,263 |
34,625 |
213,313 |
3.26%
0.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):